Sare Hosseini1, NamPhong Nguyen2, Mohammad Mohammadianpanah3, Sepideh Mirzaei4, Ali Mohammad Bananzadeh5. 1. Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Radiation Oncology, Howard University Hospital, 2401 Georgia Avenue, NW, Room 2055, Washington, DC, 20060, USA. 3. Colorectal Research Center, Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, 71936, Iran. mohpanah@gmail.com. 4. Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Colorectal Research Center, Department of Colorectal Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
INTRODUCTION: Currently, neoadjuvant fluoropyrimidine-based chemoradiation followed by surgery is considered the standard of care for locally advanced rectal cancer. The current study aimed to investigate the predictive significance of mucinous histology on the pathologic complete response rate following neoadjuvant chemoradiation in locally advanced rectal cancer and to propose potential new treatment protocol for this specific histology. MATERIAL AND METHOD: This retrospective study was conducted on 403 patients with locally advanced (clinically T3-4 and/or N1-2) rectal adenocarcinoma who had been treated at three tertiary academic hospitals between 2010 and 2015. Among those 403 patients, 46 (11%) had mucinous rectal cancer (MRC) and 358 (89%) had non-mucinous rectal cancer (NMRC). All patients underwent neoadjuvant chemoradiation with capecitabine followed by low anterior or abdominoperineal resection. RESULTS: There were 268 men and 135 women with a median age of 55 years (range, 26-82 years). Patients with MRC were younger (p = 0.002) and presented with a larger tumor size (p < 0.001) and a more advanced tumor stage (p = 0.033) compared to the ones with MNRC. In the univariate analysis, female gender (p = 0.009), distal tumor location (p = 0.035), higher tumor stage (p = 0.049), node positivity (p = 0.001), MRC histology (p = 0.017), and high pretreatment CEA level (p = 0.013) were observed to be predictive of a poor pathologic complete response. However, in the multivariate analysis, tumor stage was the single most predictive factor of response to neoadjuvant chemoradiation. CONCLUSION: Mucinous adenocarcinoma is a significant predictive factor for poor pathologic complete response to neoadjuvant capecitabine-based chemoradiation in patients with locally advanced rectal cancer. New treatment modality based on biomarkers may be considered in future prospective studies because of MRC poor prognosis. Immunotherapy combined with chemotherapy and/or radiotherapy may be an attractive option because of the tumor microsatellite instability-high status.
INTRODUCTION: Currently, neoadjuvant fluoropyrimidine-based chemoradiation followed by surgery is considered the standard of care for locally advanced rectal cancer. The current study aimed to investigate the predictive significance of mucinous histology on the pathologic complete response rate following neoadjuvant chemoradiation in locally advanced rectal cancer and to propose potential new treatment protocol for this specific histology. MATERIAL AND METHOD: This retrospective study was conducted on 403 patients with locally advanced (clinically T3-4 and/or N1-2) rectal adenocarcinoma who had been treated at three tertiary academic hospitals between 2010 and 2015. Among those 403 patients, 46 (11%) had mucinous rectal cancer (MRC) and 358 (89%) had non-mucinous rectal cancer (NMRC). All patients underwent neoadjuvant chemoradiation with capecitabine followed by low anterior or abdominoperineal resection. RESULTS: There were 268 men and 135 women with a median age of 55 years (range, 26-82 years). Patients with MRC were younger (p = 0.002) and presented with a larger tumor size (p < 0.001) and a more advanced tumor stage (p = 0.033) compared to the ones with MNRC. In the univariate analysis, female gender (p = 0.009), distal tumor location (p = 0.035), higher tumor stage (p = 0.049), node positivity (p = 0.001), MRC histology (p = 0.017), and high pretreatment CEA level (p = 0.013) were observed to be predictive of a poor pathologic complete response. However, in the multivariate analysis, tumor stage was the single most predictive factor of response to neoadjuvant chemoradiation. CONCLUSION:Mucinous adenocarcinoma is a significant predictive factor for poor pathologic complete response to neoadjuvant capecitabine-based chemoradiation in patients with locally advanced rectal cancer. New treatment modality based on biomarkers may be considered in future prospective studies because of MRC poor prognosis. Immunotherapy combined with chemotherapy and/or radiotherapy may be an attractive option because of the tumor microsatellite instability-high status.
Authors: Zoran Gatalica; Carrie Snyder; Todd Maney; Anatole Ghazalpour; Daniel A Holterman; Nianqing Xiao; Peggy Overberg; Inga Rose; Gargi D Basu; Semir Vranic; Henry T Lynch; Daniel D Von Hoff; Omid Hamid Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-12 Impact factor: 4.254
Authors: Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2017-03 Impact factor: 11.908
Authors: Doenja M J Lambregts; Vincent Vandecaveye; Brunella Barbaro; Frans C H Bakers; Maarten Lambrecht; Monique Maas; Karin Haustermans; Vincenzo Valentini; Geerard L Beets; Regina G H Beets-Tan Journal: Ann Surg Oncol Date: 2011-02-23 Impact factor: 5.344
Authors: Sare Hosseini; Ali Mohammad Bananzadeh; Roham Salek; Mohammad Zare-Bandamiri; Ali Taghizadeh Kermani; Mohammad Mohammadianpanah Journal: Ann Coloproctol Date: 2017-04-28
Authors: V Catalano; F Loupakis; F Graziano; U Torresi; R Bisonni; D Mari; L Fornaro; A M Baldelli; P Giordani; D Rossi; P Alessandroni; L Giustini; R R Silva; A Falcone; S D'Emidio; S L Fedeli Journal: Br J Cancer Date: 2009-03-03 Impact factor: 7.640
Authors: Søren R Rafaelsen; Claus Dam; Chris Vagn-Hansen; Jakob Møller; Hans B Rahr; Mikkel Sjöström; Jan Lindebjerg; Torben Frøstrup Hansen; Malene Roland Vils Pedersen Journal: Curr Oncol Date: 2022-02-13 Impact factor: 3.109